

## Engagement Report for Clinical Commissioning Policies

|  |   |
|--|---|
| <b>Unique Reference Number</b>   | 1842  |
| <b>Policy Title</b>  | Clinical Commissioning Policy Statement<br>Proton Beam Therapy for Hepatocellular Carcinoma (1842)  |
| <b>Lead Commissioner</b>   | ██████████  |
| <b>Clinical Reference Group</b>  | Radiotherapy  |
|  |   |
| Which stakeholders were contacted to be involved in policy development?  | <p>A policy working group was established in line with NHS England's standard methods.</p> <p>The draft policy proposition was sent to the following groups for comment:</p> <ul style="list-style-type: none"> <li>• Registered stakeholders for the Radiotherapy Clinical Reference Group (CRG);</li> <li>• Members of Radiotherapy CRG; and</li> <li>• Members of Hepatobiliary and Pancreatic CRG.</li> </ul>   |
| Identify the relevant Royal College or Professional Society to the policy and indicate how they have been involved | <p>The relevant Royal Colleges or Professional Societies are part of the Radiotherapy CRG or registered stakeholders, and include:</p> <ul style="list-style-type: none"> <li>• Royal College of Physicians; and</li> <li>• Royal College of Radiologists.</li> </ul> <p>Named representatives for each of these organisations were sent copies of the draft policy proposition and invited to provide comment.</p> |
| Which stakeholders have actually been involved?  | <p>7 responses were received from stakeholders.</p> <p>A response was received from the Royal College of Physicians and the Royal College of Radiologists. Additional responses were received from stakeholders including a joint response from the British Association for the Study of the Liver (BASL) and British Society of Gastroenterology (BSG), and the UK HPB precision radiotherapy steering group.</p>  |

|  |   |
|--|---|
| <p>Explain reason if there is any difference from previous question</p>  | <p>Not applicable</p>   |
| <p>Identify any particular stakeholder organisations that may be key to the policy development that you have approached that have yet to be engaged. Indicate why?</p> | <p>None identified</p>  |
| <p>How have stakeholders been involved? What engagement methods have been used?</p>  | <p>The draft commissioning policy statement was distributed to stakeholders via email for a period of two weeks of stakeholder testing, in preparation for public consultation.</p> <p>Stakeholders were asked to submit their responses via email, using a standard response and in line with NHS England's standard processes for developing clinical commissioning policies.</p> <p>Stakeholder testing asked the following questions:</p> <ul style="list-style-type: none"> <li>• Do you have any further comments on the proposed changes to the document?</li> <li>• If Yes, please describe below, in no more than 500 words, any further comments on the proposed changes to the document as part of this initial 'sense check'.</li> <li>• Please declare any conflict of interests relating to this document or service area.</li> </ul> |
| <p>What has happened or changed as a result of their input?</p>  | <p>There were 7 responses in total to stakeholder testing. All respondents were supportive of the commissioning policy statement.</p> <p>One respondent highlighted an issue with the interpretation of the evidence which was contrary to the stated position of the policy. This was discussed by the Public Health and Clinical Leads and the section removed.</p>   |

|   |   |
|---|---|
|   | 3 respondents commented that further research/trials were required. This position was endorsed by the Royal College of Physicians.  |
| How are stakeholders being kept informed of progress with policy development as a result of their input?                              | All stakeholders (including CRG members and registered stakeholders) will be notified when the final policy statement is published. |
| What level of wider public consultation is recommended by the CRG for the NPOC Board to agree as a result of stakeholder involvement? | Not applicable.   |